MAP2K7 and ovarian carcinoma: At the same time, in ovarian cancer, the dual inhibition of MEK inhibitors and the mTOR/4EBP1 signaling pathway can play a therapeutic role by modulating ferroptosis, providing a new idea for combination therapy.